SCHEMBL23200508

SCHEMBL23200508

NC(=O)Cc1cc(F)ccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
SNCA P37840 4/20 0.45
MAPT P10636 4/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 1/20 0.40
ICMT O60725 1/20 0.39
PDE7A Q13946 1/20 0.39
TTR P02766 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7594106 0.87 CYP1A2 (0.50) ATMTDP1SNCAMAPTALDH1A1
SCHEMBL3396060 0.85 CYP1A2 (0.55) ATMTDP1SNCAMAPTALDH1A1
SCHEMBL3010413 0.84 ATM (0.51) ATMTDP1SNCAMAPTALDH1A1
SCHEMBL11630295 0.83 NPC1 (0.56) ATMTDP1SNCAMAPTALDH1A1
SCHEMBL4101251 0.82 CA2 (0.43) SNCAMAPTALDH1A1CYP1A2KDM4E
SCHEMBL10615900 0.82 BACE1 (0.49) SNCAMAPTALDH1A1MAPK1CYP1A2
SCHEMBL10509627 0.81 TDP1 (0.51) ATMTDP1SNCAMAPTALDH1A1
SCHEMBL25407643 0.81 MEN1 (0.46) MAPTALDH1A1MAPK1CYP1A2KMT2A
SCHEMBL10509624 0.81 TDP1 (0.51) ATMTDP1SNCAMAPTALDH1A1
SCHEMBL30599924 0.81 MEN1 (0.46) MAPTALDH1A1MAPK1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3805214-B1 JAK3 SELECTIVE INHIBITOR UNIV PEKING SHENZHEN GRADUATE SCHOOL (CN) 2023-07-05 EP disclosed
US-11578060-B2 JAK3 selective inhibitor PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) 2023-02-14 US disclosed
CN-110551103-B JAK3 selective inhibitor 北京大学深圳研究生院 2022-08-23 CN disclosed
US-20210214344-A1 JAK3 SELECTIVE INHIBITOR PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) 2021-07-15 US disclosed
EP-3805214-A1 JAK3 SELECTIVE INHIBITOR Peking University Shenzhen Graduate School (CN) 2021-04-14 EP disclosed
CN-110551103-A JAK3 selective inhibitor SHENZHEN GRADUATE SCHOOL PEKING UNIV 2019-12-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210214344-A1 JAK3 SELECTIVE INHIBITOR JAK3, JAK1, JAK2 ATM 1152/4885TDP1 4414/4885SNCA 4279/4885
US-11578060-B2 JAK3 selective inhibitor JAK3, JAK1, JAK2 ATM 1152/4885TDP1 4414/4885SNCA 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.